{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-089530","form_type":"8-K","ticker":"BMEA","cik":"0001840439","company_name":"Biomea Fusion, Inc.","filed_at":"2023-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.075793+00:00","generated_at":"2026-06-17T07:16:00.863063+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Biomea Fusion prices upsized $150M public offering of 5M shares at $30; net proceeds ~$161.6M","bullets":["Offering of 5,000,000 shares at $30.00 per share; gross proceeds of $150.0 million.","Underwriters exercised 30-day option to purchase additional 750,000 shares in full.","Net proceeds of approximately $161.6 million after underwriting discounts and expenses.","Proceeds to fund clinical development of BMF-219 (menin inhibitor) and BMF-500 (FLT3 inhibitor).","J.P. Morgan and Citigroup acted as joint book-running managers; closing on April 3, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-089530","json":"https://secwatch.observer/filing/0001193125-23-089530.json","markdown":"https://secwatch.observer/filing/0001193125-23-089530.md","text":"https://secwatch.observer/filing/0001193125-23-089530.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1840439/000119312523089530/0001193125-23-089530-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1840439/000119312523089530/d486927d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T07:16:00.863063+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1c242eae42c432c4acfad67aa90b9ffc456c7fb6","claim":"Biomea Fusion, Inc. entered into Underwriting Agreement with J.P. Morgan Securities LLC and Citigroup Global Markets Inc. valued at 5,000,000 shares of common stock at $30.00 per share, with option for additional 750,000 shares, agg (effective 2023-03-29).","evidence_excerpt":"On March 29, 2023, Biomea Fusion, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreemen t ”) with J.P. Morgan Securities LLC and Citigroup Global Markets Inc., as representatives of the several underwriters named therein (the “Underwriters”) pursuant to which the Company agreed to issue and sell 5,000,000 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), to the Underwriters at a public offering price of $30.00 per share (the “Offering”). Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 750,000 shares of Common Stock at the same price per share (the “Option Shares”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1840439/000119312523089530/0001193125-23-089530-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"J.P. Morgan Securities LLC and Citigroup Global Markets Inc."},{"label":"Value","value":"5,000,000 shares of common stock at $30.00 per share, with option for additional 750,000 shares, agg"},{"label":"Effective","value":"2023-03-29"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}